NCT02639065 - A Study of Durvalumab (MEDI4736) in Esophageal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 27, 2016

Primary Completion Date

December 9, 2020

Study Completion Date

June 9, 2021

Conditions

Esophageal Cancer

Interventions

DRUG

Durvalumab

1500 mg IV every 4 weeks (1 cycle) for a maximum 13 doses (12 months), or until unacceptable toxicities or disease recurrence.

Trial Locations (3)

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

University of Michigan Health System, Ann Arbor

Unversity of Iowa Hospital and Clinics, Iowa City